Isis Pharmaceuticals collaborated with Ortho-McNeil, a unit of Johnson & Johnson, for the development and marketing of two of its experimental diabetes drugs. Ortho-McNeil agreed to pay a licensing fee of $45 million for the diabetes drug of Isis, and will provide research and development funding to Isis to develop treatment for metabolic disorders.